Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
|09 Sep 2021||$0.0800||100.00%||Final||01 Oct 2021|
|04 Mar 2021||$0.0700||100.00%||Interim||19 Mar 2021|
|10 Sep 2020||$0.0600||100.00%||Final||02 Oct 2020|
|05 Mar 2020||$0.0600||100.00%||Interim||20 Mar 2020|
|12 Sep 2019||$0.0450||100.00%||Final||04 Oct 2019|
|12 Mar 2019||$0.0250||100.00%||Special Cash||17 May 2019|
|07 Mar 2019||$0.0350||100.00%||Interim||22 Mar 2019|
|06 Sep 2018||$0.0350||100.00%||Final||27 Sep 2018|
|08 Mar 2018||$0.0250||100.00%||Interim||23 Mar 2018|
|07 Sep 2017||$0.0250||100.00%||Final||28 Sep 2017|
|08 Sep 2016||$0.0150||0.00%||Final||29 Sep 2016|
|10 Mar 2016||$0.0150||0.00%||Interim||24 Mar 2016|
|09 Sep 2015||$0.0100||0.00%||02 Oct 2015|
|04 Mar 2015||$0.0100||0.00%||20 Mar 2015|
|10 Sep 2014||$0.0100||100.00%||03 Oct 2014|
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Pro Medicus Limited (ASX: PME) provides healthcare imaging software and services to hospitals, diagnostic imaging groups and other health related entities in Australia, North America and Europe.
The company is a leading provider of radiology information systems (RIS), picture archiving and communication systems (PACS) and advanced visualisation solutions across the globe. It has more than 30 years’ experience in helping clients deliver first-rate patient care by enhancing and streamlining medical practice management.
Primary products for RIS include medical accounting, clinical reporting, appointments/scheduling and marketing/ management information applications.
After explosive growth in 2019, the Pro Medicus share price has been able to successfully navigate the impacts of COVID-19 in 2020.
|03 Dec 2021||$57.78||$2.11||3.79%||243,017||$55.93||$57.98||$55.93|
|02 Dec 2021||$55.67||$-2.19||-3.78%||359,904||$56.50||$57.26||$53.93|
|01 Dec 2021||$57.86||$-4.62||-7.39%||259,239||$61.80||$61.91||$57.67|
|30 Nov 2021||$62.48||$0.79||1.28%||198,994||$62.00||$63.49||$61.90|
|29 Nov 2021||$61.69||$0.45||0.73%||218,032||$60.51||$62.21||$60.00|
|26 Nov 2021||$61.24||$-0.58||-0.94%||107,977||$61.85||$62.05||$60.81|
|25 Nov 2021||$61.82||$1.92||3.21%||162,335||$60.26||$62.08||$59.28|
|24 Nov 2021||$59.90||$-0.13||-0.22%||148,217||$58.22||$60.22||$57.37|
|23 Nov 2021||$60.03||$-2.70||-4.30%||148,584||$62.10||$62.25||$59.69|
|22 Nov 2021||$62.73||$0.48||0.77%||127,227||$62.40||$63.80||$61.92|
|19 Nov 2021||$62.25||$0.60||0.97%||86,674||$61.66||$62.48||$61.05|
|18 Nov 2021||$61.65||$-0.17||-0.27%||127,392||$61.55||$61.70||$60.56|
|17 Nov 2021||$61.82||$0.47||0.77%||130,027||$61.54||$62.40||$61.15|
|16 Nov 2021||$61.35||$0.36||0.59%||107,920||$60.90||$61.46||$60.02|
|15 Nov 2021||$60.99||$2.12||3.60%||138,601||$59.50||$61.32||$59.50|
|12 Nov 2021||$58.87||$0.34||0.58%||80,637||$58.39||$59.03||$58.19|
|11 Nov 2021||$58.53||$-0.79||-1.33%||105,194||$58.95||$59.29||$58.20|
|10 Nov 2021||$59.32||$0.44||0.75%||92,172||$58.80||$59.50||$58.35|
|09 Nov 2021||$58.88||$-0.43||-0.73%||140,035||$58.99||$59.13||$57.26|
|08 Nov 2021||$59.31||$-1.87||-3.06%||214,617||$62.77||$62.77||$59.13|
|05 Nov 2021||$61.18||$2.30||3.91%||296,953||$59.80||$61.18||$59.44|
|04 Nov 2021||$58.88||$1.88||3.30%||239,377||$57.57||$59.09||$57.06|
|30 Nov 2021||Alice Williams||Buy||400||$24,800|| |
|18 Feb 2021||Sam Hupert||Sell||1||$45,970,000|| |
|18 Feb 2021||Anthony Hall||Sell||1||$45,970,000|| |
|Dr Sam Aaron Hupert||Chief Executive OfficerManaging Director||Oct 2007|| |
Dr Hupert is a Monash University Medical School graduate who commenced General Practice in 1980. Realising the significant potential for computers in medicine he left general practice in late 1984 to devote himself full time to managing the Group.
|Mr Anthony Barry Hall||Executive DirectorTechnology Director||Jan 1983|| |
Mr Hall has been principal architect and developer of the core software systems. His current focus is the transition to and development of the Company's next generation RIS systems.
|Mr Peter Terence Kempen||Non-Executive ChairmanNon-Executive Director||Mar 2008|| |
Mr Kempen is Chairman of Australasian Leukaemia and Lymphoma Group and Chairman of Logie- Smith Lanyon. He is also a Trustee of the Barr Family Foundation and a member of the Board of St Hilda's College Ltd, University of Melbourne. Peter has previously been Chairman of Patties Food Limited, Chairman of Danks Holdings Limited, Chairman of Ivanhoe Grammar School and Managing Partner of Ernst & Young Corporate Finance Australia. Peter was appointed a Member in the General Division of the Order of Australia (AM) in the 2018 Queen's Birthday Honours. Peter became Chairman in August 2010 before which he served as a Non-Executive Director of the Company. Peter is also Chair of the Risk committee.
|Ms Alice Joan Morrice Williams||Non-Executive Director||Sep 2021|| |
Ms Williams has had worked on range of executive roles in the financial services sector including Vice President at JP Morgan as an institutional investor with responsibility for equity investments in transport, industrial companies & infrastructure. Former senior executive roles include Director Strategy & Fleet Planning in the aviation sector. Over her career she has gained experience in risk management, including technology and cybersecurity risks as well as governance of technology projects involving outsourcing, cloud hosting and offsite support. Alice has had Board roles on ASX listed companies, including Djerriwarrh Investments Limited (current), Equity Trustees Limited and Cooper Energy Limited. She is currently a Director of Defence Health Limited, Mercer Investments (Australia) Limited and has recently joined the Board of Vocus Communications Limited. In several of these organizations Alice has been a member of, or Chair, of the Audit and Risk Committee. In addition, Alice has served on a number of Government Boards, including the Foreign Investment Review Board, Port of Melbourne Corporation, Victorian Funds Management Corporation and Airservices Australia. She has several positions in not-for-profit organizations which are primarily focused on health. She will also appoint as Chair of the Risk Committee of PME effective from 01/09/2021.
|Ms Deena Robyn Shiff||Non-Executive Director||Aug 2020|| |
Ms Shiff also holds other board positions with Healthcare I.T. Pty Ltd, Infrastructure Australia and Opera Australia and is Chair of the Government's Australia Broadband Advisory Council. Previous board roles include Chairman of the global board of BAI Communications, Vice Chairman of the Government's Export Credit Agency EFIC , and a number of venture capital backed growth stage ICT companies. Deena has served as a Group Managing Director at Telstra, where she led the Wholesale Division Group, established and led Telstra Business and founded Telstra's corporate venture capital arm, Telstra Ventures. Deena has also held various in house regulatory and legal positions and has been a Partner of the law firm Mallesons Stephen Jacques.
|Mr Anthony James Glenning||Non-Executive Director||May 2016|| |
Mr Glenning is the fund manager of Skalata Ventures, investing in early stage companies to help them scale and grow into significant and sustainable businesses. Anthony has previously been Chairman of Cyrise Pty Ltd, an accelerator for early stage cyber security start-ups and Investment Director of Starfish Ventures and was the founder and previously the CEO of Tonic Systems and a founding Non-Executive Director of Cameron Systems. Anthony also serves on the People & Culture committee and Risk committee.
|Dr Leigh Bernard Farrell||Non-Executive Director||Sep 2017|| |
Dr Farrell is the Head of the Health Security Division of DMTC Ltd, Managing Director of AdNED Pty Ltd, non-executive director of both Ena Respiratory Pty Ltd and Alexia Oncology Pty Ltd, a member of the Walter and Eliza Hall Institute of Medical Research Board Commercialisation Committee and a member of the Independent Advisory Council of Medicines Australia. Leigh was previously Senior Vice President, Commercial of Certara USA, Inc. where he was responsible for Asia Pacific Commercial. Prior to this, he was Chairman and COO of d3 Medicine LLC, which was acquired by Certara USA, Inc. Leigh also serves on the People & Culture committee and Risk committee.
|Mr Clayton James Hatch||Chief Financial OfficerCompany Secretary||Jul 2009|| |
|Clayton James Hatch||Chief Financial OfficerCompany Secretary|| |
|Danny Tauber||General Manager - Pro Medicus Limited|| |
|Brad Levin||General Manager - Visage Imaging Inc.|| |
|Sean Lambright||Global Head of Sales - Visage Imaging Inc|| |
|Malte Westerhoff||Managing Director - Visage Imaging GmbH|| |
|Dr S Hupert (multiple shareholdings)||27,137,660||26.04%|
|Mr A Hall (multiple shareholdings)||27,109,000||26.01%|
|HSBC Custody Nominees (Australia) Limited||13,423,186||12.88%|
|J P Morgan Nominees Australia Limited||5,695,125||5.46%|
|Citicorp Nominees Pty Ltd||5,338,280||5.12%|
|National Nominees Limited||2,441,254||2.34%|
|BNP Paribas Noms Pty Ltd||702,375||0.67%|
|Mr Peter Terence Kempen & Mrs Elaine Margaret Kempen (multiple shareholdings)||678,082||0.65%|
|Mr Bram Vander Jagt & Mrs Maaike Vander Jagt||650,000||0.62%|
|Grain Exporters (Australia) Pty Ltd||500,000||0.48%|
|Mr Michael Wu||431,244||0.41%|
|BNP Parabis Nominees Pty Ltd||349,719||0.34%|
|Mr Roderick Lyle (multiple shareholdings)||320,000||0.31%|
|Mr Evan Philip Clucas and Ms Leanne Jane Weston||287,980||0.28%|
|BNP Parabis Nominees Pty Ltd Six Sis Ltd||285,197||0.27%|
|Mr Stephen Geoffrey Wilson & Ms Denise Adele Prandi||285,037||0.27%|
|Mr Danny Tauber||279,326||0.27%|
|Mr Colin Gregory Organ||271,000||0.26%|
|Mr John Charles Plummer||250,000||0.24%|
Pro Medicus is a leading imaging IT provider that provides radiology IT software and services to hospitals, imaging centers and health care groups worldwide.
PME’s most recent dividend payment was made to shareholders March 20, with the distribution amount being $0.06.